The purpose of this memo is to notify AIDS Drug Assistance Program (ADAP) Enrollment Workers and providers about new additions to the ADAP Open Formulary since its launch in January 2026. These additions enhance access to essential therapies for clients statewide and reflect ADAPs ongoing commitment to providing broader pharmaceutical coverage.
Medications Added to the ADAP Formulary (January–June 2026)
Aficamten (Myqorzo)
| Lusutrombopag (Mulpleta) |
| Etripamil (Cardamyst) | Plozasiran Sodium (Redemplo) |
| Verteporfin (Visudyne) |
|
Benfotiamine
| MVW Modulator Formulation Multivitamin Chew |
Hydroxocobalamin/Cobamamide (Adeno-Hydroxo B12)
| Vitamin D3 / K2 Combination (K2-D3 Max) |
| Hydroxyapatite (Ossopan 1100) |
|
Benzocaine (20% spray)
| Benzocaine/Menthol/Cetylpyridinium Chloride (Orasep solution) |
Benzocaine/Benzalkonium Chloride – Oral Pain Relief Gel
| Benzocaine/Menthol (Toothache Relief, CVS) |
| Benzocaine/Menthol/Zinc/Benzalkonium (Orajel 4X Toothache-Gum Gel) | Chlorhexidine Gluconate 0.12% rinse
|
| Semaglutide (Wegovy HD) – Anti-Obesity | Tapinarof (Vtama) – Dermatologic |
| Oravig (miconazole buccal tablet) |
|
*Prior Authorization required as the use of long-acting cabotegravir without long-acting rilpivirine has not been studied in clinical trials. Consult a clinical HIV expert if a treatment regimen with long acting cabotegravir combined with other antiretrovirals is being designed.
Note: Several diabetic supply products appear in the dataset but are not included here, as they represent new manufacturers or brands rather than new formulary categories.
The full, regularly updated ADAP Open Formulary is linked.
The consolidated, regularly updated ADAP Open Formulary is linked.
For questions regarding pharmacy access or how to locate a pharmacy, please visit the Prime Therapeutics CDPH homepage.
For questions regarding this memo, please contact your OA Advisor.
Thank you,
Joseph Lagrama
ADAP Branch Chief
California Department of Public Health